Evidence map›Paper›PMID 41868871›Full record

ArticleAnnals of gastroenterology

Gaps in the diagnosis of small bowel adenocarcinoma among patients with Crohn's disease: a tertiary care perspective.

Marisa-Nicole S Zayat, Micah Vander Griend, Jana G Hashash, Jami Kinnucan, Michael Picco, Francis A Farraye, Rex K Siu

Abstract read
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marisa-Nicole S ZayatDepartment of Internal Medicine, Mayo Clinic Florida, USA (Marisa-Nicole S. Zayat, Micah Vander Griend, Rex K. Siu).
Micah Vander GriendDepartment of Internal Medicine, Mayo Clinic Florida, USA (Marisa-Nicole S. Zayat, Micah Vander Griend, Rex K. Siu).
Jana G HashashDepartment of Gastroenterology and Hepatology, Mayo Clinic Florida, USA (Jana G. Hashash, Jami Kinnucan, Michael Picco, Francis A. Farraye).
Jami KinnucanDepartment of Gastroenterology and Hepatology, Mayo Clinic Florida, USA (Jana G. Hashash, Jami Kinnucan, Michael Picco, Francis A. Farraye).
Michael PiccoDepartment of Gastroenterology and Hepatology, Mayo Clinic Florida, USA (Jana G. Hashash, Jami Kinnucan, Michael Picco, Francis A. Farraye).
Francis A FarrayeDepartment of Gastroenterology and Hepatology, Mayo Clinic Florida, USA (Jana G. Hashash, Jami Kinnucan, Michael Picco, Francis A. Farraye).
Rex K SiuDepartment of Internal Medicine, Mayo Clinic Florida, USA (Marisa-Nicole S. Zayat, Micah Vander Griend, Rex K. Siu).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Small bowel adenocarcinoma (SBA) is a rare and serious complication of Crohn's disease (CD), with symptoms often mimicking CD-related symptoms. Therefore, preoperative diagnosis of SBA is difficult, since conventional imaging is rarely diagnostic. This study aims to evaluate the utility of imaging and endoscopic modalities in detecting SBA among patients with CD. Methods: A retrospective review of medical records from a multi-institutional tertiary care center was conducted. ICD-10 codes were used to identify patients with CD who were diagnosed with SBA between January 1, 2019, and November 24, 2024. Results: Of 92 patients identified, 36 met the inclusion criteria. Twenty-one (58.3%) were male, and 35 (97.2%) were Caucasian. The median age at SBA diagnosis was 61 years, with a median 19-year interval from initial CD diagnosis to SBA diagnosis. Thirty-one patients (86.1%) had preoperative imaging, but only 7/31 (22.6%) had findings that raised concern for malignancy. Eight (22.2%) of the patients who underwent endoscopy were diagnosed with SBA or dysplasia on endoscopic biopsy; 18 cases were discovered incidentally during surgery. Sixteen patients (44.4%) had stage III or IV cancer at diagnosis, and 18 patients (50.0%) achieved oncologic remission. Conclusions: Among patients with CD diagnosed with SBA, a large proportion of imaging and endoscopic studies failed to suggest malignancy. Given the substantial proportion of patients diagnosed at advanced stages, and the associated poor outcomes, a high index of suspicion and multimodal evaluation could improve the diagnostic yield in long-standing CD patients with new or changing symptoms.

Indexed as

Crohn’s diseasegastrointestinal malignancyinflammatory bowel diseaseSmall bowel adenocarcinomasmall bowel cancer

Identifiers

PMID41868871
PMCPMC13004815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.